Back to top
more

Ascendis Pharma (ASND)

(Delayed Data from NSDQ)

$134.46 USD

134.46
223,436

-0.85 (-0.63%)

Updated Jun 4, 2024 04:00 PM ET

After-Market: $134.55 +0.09 (0.07%) 5:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ASND

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Ascendis Pharma A/S [ASND]

Reports for Purchase

Showing records 101 - 120 ( 303 total )

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 101

10/31/2022

Company Report

Pages: 8

TC-PTH/HP NDA Accepted for Priority Review, PDUFA Set for April 30, 2023

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 102

10/05/2022

Daily Note

Pages: 9

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 103

10/04/2022

Company Report

Pages: 8

TC-PTH U.S./EU Opportunity Opens Up with Natpara/Natpar Discontinuation by YE24

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 104

09/29/2022

Company Report

Pages: 8

TC-PTH Blockbuster Potential Coming into Focus; Adding to BIL

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 105

09/13/2022

Daily Note

Pages: 9

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 106

09/13/2022

Company Report

Pages: 9

110wk PaTH Forward OLE Results for TC-PTH/HP Highlight Durability of Response

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 107

09/01/2022

Industry Report

Pages: 16

Monthly Check-Up: September 2022

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 108

08/15/2022

Industry Report

Pages: 7

Wedbush Healthcare Conference - That''s A Wrap; Key Takeaways

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 109

08/11/2022

Daily Note

Pages: 14

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 110

08/11/2022

Company Report

Pages: 8

Q2: SKYTROFA Sales SKYrocket; Multiple Value-Driving Catalysts in H2

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 111

06/15/2022

Industry Report

Pages: 11

E.N.D.O - Exploring New Drug Opportunities in Endocrinology KOL Call Highlights

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 112

06/13/2022

Industry Report

Pages: 11

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 113

05/12/2022

Company Report

Pages: 8

Q1: SKYTROFA''s Shaky Start Not Surprising; Eyes on the Prize with TC-PTH/HP

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 114

05/08/2022

Daily Note

Pages: 11

HEALTHCARE- The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 115

04/13/2022

Company Report

Pages: 8

Model Update Ahead of Q1:22, Upcoming Catalysts

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 116

04/13/2022

Daily Note

Pages: 8

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 117

03/28/2022

Daily Note

Pages: 13

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 118

03/28/2022

Company Report

Pages: 22

Ascending to Greater Heights; Assuming at OUTPERFORM & $163 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: ARGYRIDES A

Price: 35.00

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 119

03/14/2022

Company Report

Pages: 9

Topline PaTHway Ph3 Results; Positive at First Blush but Further Clarity Needed

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 12.50

Research Provided by a Third Party

Company: Ascendis Pharma A/S

Industry: Medical - Biomedical and Genetics

Record: 120

03/14/2022

Daily Note

Pages: 12

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party